I'll be straight with you -- if someone asks why I'm holding Pfizer and have zero intention of selling, the answer's pretty simple. I'm already in it, and I don't see a reason to get out.

Pfizer's had a rough stretch lately, no question about it. The stock's been sluggish, averaging just 6.5% annual gains over the past 15 years, and it's actually down 8.8% annually over the last three years. But here's what caught my attention and keeps me invested: that dividend is sitting at 6.4% yield right now. We're talking about a company that's paid out 349 consecutive quarterly dividends. That's 29 years of uninterrupted payments. You don't see that kind of consistency everywhere.

Look, Pfizer's a pharmaceutical heavyweight with a market cap around $154 billion. They've been around since 1849 -- they survived the Civil War, the Great Depression, everything. When COVID hit, they became a household name with their vaccine and Paxlovid treatment. Those products printed money for them, but obviously that revenue stream has normalized. The market's repriced the stock accordingly, which actually makes it interesting right now. Forward P/E ratio is hovering around 8.8, below the five-year average of 9.8.

What keeps me from walking away? The pipeline. Yes, some of their major drugs are facing patent cliffs -- that's real. But the company isn't sitting idle. They've got 102 candidates in development, with 32 of them in late-stage Phase 3 trials. They're even investing in GLP-1 drugs, which is where the market's attention is right now. In 2025, they plowed $10.4 billion into R&D. That's serious money going toward innovation.

The dividend growth hasn't been explosive -- averaging about 3% annual increases over five years -- but it's steady and reliable. That's actually what appeals to me. I'm not betting on this becoming a moonshot stock. I'm collecting that income while the company works on its next generation of products.

Recent numbers show revenue down 3% year-over-year, but that's because COVID products have faded. Strip those out and you get 9% operational growth in Q4, with 6% operational growth across all of 2025. That's the underlying business performing decently.

I won't pretend this is a buy-it-and-forget-it situation. You need to keep tabs on their pipeline progress and make sure the dividend stays sustainable. But right now, at this valuation with this yield, I'm happily staying put. The way I see it, if you're looking for steady income and believe in their R&D execution, this could work for you too. Just do your homework on their pipeline before committing -- that's where the real story unfolds.